secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001564590-23-003928
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology board changes: Vlad resigns, Theagène elected, Smith joins audit committee
--------------------------------------------------------------------------------

- Laurentiu Vlad resigned as Class III director and audit committee member effective March 16, 2023, citing personal reasons; no disagreement with the company.
- Jean-Manassé Theagène elected as Class III director to fill the vacancy, effective March 17, 2023, until the 2025 annual meeting.
- Stan Smith appointed to the audit committee on March 16, 2023, filling the vacancy from Vlad's resignation.
- Theagène will receive standard independent director compensation and enter into an indemnification agreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023003928/0001564590-23-003928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023003928/maia-8k_20230313.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-003928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer